Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Niue Health Report.
Press releases published on June 23, 2025
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
GlobeNewswire
·
June 23, 2025
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphoma EO2463 plus R2 combination treatment resulted in …
141,959 Orion Corporation A shares converted into B shares
GlobeNewswire
·
June 23, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 23 June 2025 at 9.30 EEST 141,959 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of …
141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi
GlobeNewswire
·
June 23, 2025
ORION OYJ PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT 23.6.2025 KLO 9.30 141 959 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 141 959 A- …
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
GlobeNewswire
·
June 23, 2025
PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB’S POTENTIAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE THROUGH A DUAL MECHANISM OF COGNITIVE ENHANCEMENT AND NEUROPROTECTION THIS PUBLICATION CORROBORATES NEW ANALYSIS FROM THE …
AB Science - De nouvelles données évaluées par des pairs apportent des preuves solides du potentiel du masitinib dans le traitement de la maladie d’Alzheimer
GlobeNewswire
·
June 23, 2025
COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES ÉVALUÉES PAR DES PAIRS APPORTENT DES PREUVES SOLIDES DU POTENTIEL DU MASITINIB DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER GRÂCE À UN DOUBLE MÉCANISME D'AMÉLIORATION COGNITIVE ET DE NEUROPROTECTION CETTE …
New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential
GlobeNewswire
·
June 23, 2025
Press Release Carmil Therapeutics to develop next-generation immunotherapies based on this innovation Paris …
Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors
GlobeNewswire
·
June 23, 2025
MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the appointment of two highly accomplished …
Galapagos Appoints Aaron Cox as Chief Financial Officer
GlobeNewswire
·
June 23, 2025
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext …
Galapagos benoemt Aaron Cox als Chief Financial Officer
GlobeNewswire
·
June 23, 2025
Voormalig CFO van Horizon vervoegt Galapagos met diepgaande expertise in internationale bedrijfsfinanciering, fusies en overnames, bedrijfsontwikkeling en strategisch leiderschap Mechelen, België; 23 juni 2025, 07:30 CET; gereglementeerde informatie - …
SBC Medical Participated in 4 Investor Conferences in May and June 2025
GlobeNewswire
·
June 23, 2025
IRVINE, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, recently participated in several prominent investor conferences …
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
GlobeNewswire
·
June 23, 2025
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity …
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
GlobeNewswire
·
June 23, 2025
Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe Recommandation fondée sur l’étude de phase 3 GMMG-HD7, qui a montré que l’ajout de Sarclisa …